摘要
目的研究汉防己甲素对矽肺患者的临床效果。方法对我院收治的66例矽肺病I期患者,随机分为实验组34例,对照组32例。实验组在对照组的基础上加用汉防己甲素40mg口服,每天三次,疗程6个月,对照组使用安慰剂。比较两组治疗前后的症状积分、和各实验室指标、X线报告好转率以及副作用。结果实验组治疗后的症状评分要显著优于对照组(P<0.05),治疗总有效率也优于对照组(P<0.05);实验组治疗后肺功能指标和动脉血气指标要明显优于对照组(P<0.05),胸片好转率也优于对照组。结论汉防己甲素可以明显缓解矽肺患者的临床症状,抑制肺纤维化,值得临床上推广使用。
Objective To study the clinical effect of tetrandrine on silicosis. Methods 66 patients with sil- icosis at stage I were randomly divided into the experimental group （ n = 34） and the control group （n = 32）. On the basis of the control group, the experimental group was additionally given tetrandrine hormone 40mg orally, three times a day for 6 months, and the control group was treated with placebo. Symptom scores were compared before and after the treatment, and various laboratory tests, X-ray reports improved rates and side effects were analyzed. Results The scores of symptom after the treatment was significantly better in the experimental group than in the control group （ P 〈 0.05 ）, the total efficiency was better in the experimental group than in the control group （ P 〈 0.05 ）, their pulmonary function and arterial blood gas index was significantly superior in the experimental group than in the control group （ P 〈 0.05 ）, and the improvement rate of chest X-ray report was also better in the experimental group than in the control group. Conclusion Tetrandrine hormone can significantly relieve their clinical symptoms and inhibit pul-monary fibrosis in the treatment of silicosis patients.
出处
《临床肺科杂志》
2015年第9期1658-1661,共4页
Journal of Clinical Pulmonary Medicine
关键词
矽肺
汉防己甲素
肺纤维化
silicosis
tetrandrine hormone
pulmonary fibrosis
